TGFB1 and non-small cell lung carcinoma: Pirfenidone has been shown to synergize with cisplatin in killing tumor cells and CAFs in NSCLC cells (37) as well as to act synergistically with doxorubicin in a triple-negative breast cancer (TNBC) model and inhibiting tumor fibrosis and TGFβ signaling (38); although individual effects of Pirfenidone on tumor growth and lung metastases were not evaluated so far.